Vitality Watch

Dossier clinicaltrials trial early 05-aug-2026
Small or early-phase human trial or pilot study

Mitochondrial-targeted Antioxidant Supplementation for Improving Age-related Vascular Dysfunction in Humans

Key claim: A randomized, placebo-controlled trial is testing whether 20 mg/day oral MitoQ for 3 months improves endothelial function and aortic stiffness in adults ≥60 years by reducing mitochondrial ROS.

Abstract

The majority of cardiovascular diseases (CVD) occur in men and women ≥60 years of age. Vascular dysfunction, including endothelial dysfunction, as assessed by reduced endothelium-dependent dilation (EDD), and stiffening of the large elastic arteries (i.e., aortic and carotid artery stiffening), is a major mechanism of increased risk of CVD in older adults. Excess production of ROS (reactive oxygen species) by mitochondria (mtROS) has emerged as a central feature of vascular oxidative stress with aging and driver of age-related vascular dysfunction. As such, identifying novel strategies to decrease mtROS and improve vascular function, to ultimately reduce the risk of age-related CVD, is an important biomedical objective.

MitoQ is a mitochondria-targeted antioxidant that accumulates at the inner mitochondrial membrane where it is optimally positioned to reduce mtROS. Preclinical findings showed that 4 weeks of oral MitoQ supplementation completely restored EDD in old mice, ameliorated mtROS-associated suppression of EDD, and was associated with reduced arterial mtROS, oxidative stress, and improved mitochondrial health. MitoQ therapy also reduced aortic stiffness in old mice. A recent small pilot study of older adults (n=20) found that supplementation with MitoQ was well-tolerated, improved endothelial function, and reduced plasma levels of oxidized low-density lipoprotein, a circulating biomarker of oxidative stress. Consistent with the preclinical findings, preliminary mechanistic assessments in subsets of subjects from the pilot study suggested that improved endothelial function with MitoQ was mediated by reduced endothelial cell mtROS production, associated reductions in tonic mtROS-related suppression of EDD, and improved mitochondrial health, linked in part to changes in circulating factors in the serum induced by chronic MitoQ supplementation. Lastly, MitoQ reduced aortic stiffness in older adults who exhibited age-related aortic stiffening at baseline.

The investigators are conducting a randomized, placebo-controlled, double-blind clinical trial to establish oral MitoQ (20 mg/day; MitoQ, Ltd.) for 3 months vs. placebo (n=56/group) for improving endothelial function in older men and women (≥60 years), and determine the mechanisms by which MitoQ improves endothelial function. The investigators will also assess the effect of MitoQ on aortic stiffness.

Why this matters

Age-related vascular dysfunction has been mechanistically pinned to mitochondrial ROS in rodent models and a small human pilot, but the mtROS-targeting narrative has not yet been confirmed by adequately powered human trials. This RCT is a confirmatory rather than picture-changing test — a rare instance where a mitochondrial hallmark is being probed with a prespecified vascular endpoint in older adults, and its readout will constrain how much the mouse-to-human translation of mtROS interventions can be trusted.

Source

Link

Briefing card

Mitochondrial-targeted Antioxidant Supplementation for Improving Age-related Vascular Dysfunction in Humans
Stage: trial early · clinicaltrials · 05-aug-2026

If you are an older adult taking MitoQ for vascular aging, a properly powered trial is now testing whether the 20 mg/day dose actually improves endothelial function and arterial stiffness.

A randomized, placebo-controlled trial is testing whether 20 mg/day oral MitoQ for 3 months improves endothelial function and aortic stiffness in adults ≥60 years by reducing mitochondrial ROS.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT04851288

build build 880 · 2bcef25 · 2026-11-18